Abstract
The metastatic triple negative breast cancer (mTNBC) represents a particularly aggressive form of breast cancer that frequently affects young women under the age of 50. Obesity at the time of breast cancer diagnosis is associated with a worse prognosis. Compared to the recent past, increasing life expectancy and quality of life for patients with mTNBC is now a possible challenge, thanks to a new drug, sacituzumab govitecan (SG), an anti-Trop-2 antibody drug conjugate approved as monotherapy for the treatment of these patients. The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adult
-
Antibodies, Bispecific / administration & dosage
-
Antibodies, Bispecific / adverse effects
-
Antibodies, Bispecific / pharmacology
-
Antibodies, Monoclonal, Humanized* / administration & dosage
-
Antibodies, Monoclonal, Humanized* / adverse effects
-
Antibodies, Monoclonal, Humanized* / pharmacology
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Body Mass Index*
-
Camptothecin* / administration & dosage
-
Camptothecin* / analogs & derivatives
-
Camptothecin* / therapeutic use
-
Female
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / adverse effects
-
Immunoconjugates / pharmacology
-
Obesity* / complications
-
Obesity* / drug therapy
-
Quality of Life*
-
Time Factors
-
Treatment Outcome
-
Triple Negative Breast Neoplasms* / drug therapy
-
Triple Negative Breast Neoplasms* / pathology
Substances
-
sacituzumab govitecan
-
Antibodies, Monoclonal, Humanized
-
Camptothecin
-
Antibodies, Bispecific
-
Immunoconjugates
-
Antineoplastic Agents